Haiyan Yang
Changsha, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial.
Journal: Cell reports. Medicine
Published: January 07, 2026
High-dose furmonertinib as first-line treatment for untreated EGFR-mutated advanced NSCLC with central nervous system metastases: A phase 2 trial.
Journal: Cell reports. Medicine
Published: October 21, 2025
Efficacy, safety, and exploratory biomarker analysis of rechallenge with immune checkpoint inhibitors combined with anlotinib in previously treated advanced non-small cell lung cancer.
Journal: BMC pulmonary medicine
Published: September 18, 2025
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial.
Journal: Nature communications
Published: September 13, 2025
Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.
Journal: Nature medicine
Published: July 22, 2025
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study.
Journal: The Lancet. Oncology
Published: October 30, 2024
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial.
Journal: Med (New York, N.Y.)
Published: August 14, 2024
Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 27, 2022
Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.
Journal: BMC cancer
Published: June 24, 2022
PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study.
Journal: Frontiers in oncology
Published: March 31, 2022
The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study.
Journal: Translational lung cancer research
Published: January 17, 2022
Last Updated: 09/26/2026